Treatment of chronic immune thrombocytopenic purpura in adults
- First Online:
- Cite this article as:
- Godeau, B. & Michel, M. Ann Hematol (2010) 89(Suppl 1): 55. doi:10.1007/s00277-010-0952-y
- 172 Downloads
Until recently, the management of refractory immune thrombocytopenic purpura (ITP) was a real challenge as shown by the large variety of treatments proposed in both American Society of Hematology and the British Committee for Standards in Haematology guidelines published 10 and 6 years ago, respectively. However, as in the past 5 years, new therapeutic approaches including eradication of Helicobacter pylori in infected patients and rituximab have been proposed and the thrombopoietin-receptor agonists have been developed and licensed for ITP. It is likely that the therapeutic strategy of ITP will be profoundly modified and revisited in the next future. The purpose of this article is to discuss the impact and the place of these new therapeutic options into the whole treatment strategy of chronic ITP and to draw the perspective of new experimental therapies.